Axsome Therapeutics (AXSM) Gross Margin: 2022-2025
Historic Gross Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to 93.03%.
- Axsome Therapeutics' Gross Margin rose 109.00% to 93.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.86%, marking a year-over-year increase of 78.00%. This contributed to the annual value of 91.37% for FY2024, which is 100.00% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Gross Margin is 93.03%, which was up 2.19% from 91.04% recorded in Q2 2025.
- Axsome Therapeutics' Gross Margin's 5-year high stood at 93.03% during Q3 2025, with a 5-year trough of 88.58% in Q3 2022.
- For the 3-year period, Axsome Therapeutics' Gross Margin averaged around 91.09%, with its median value being 91.15% (2024).
- Per our database at Business Quant, Axsome Therapeutics' Gross Margin plummeted by 91bps in 2023 and then spiked by 325bps in 2024.
- Quarterly analysis of 4 years shows Axsome Therapeutics' Gross Margin stood at 90.60% in 2022, then crashed by 91bps to 89.69% in 2023, then soared by 146bps to 91.15% in 2024, then surged by 109bps to 93.03% in 2025.
- Its Gross Margin was 93.03% in Q3 2025, compared to 91.04% in Q2 2025 and 91.94% in Q1 2025.